Potent cationic inhibitors of west Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity

Journal of Medicinal Chemistry

Volumn 51, Issue 18, 2008, Pages 5714-5721

  Stoermer, Martin J ^a   Chappell, Keith J ^a   Liebscher, Susann ^a   Jensen, Christina M ^a   Gan, Chun H ^a   Gupta, Praveer K ^a   Xu, Wei Jun ^a   Young, Paul R ^a   Fairlie, David P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN BHK; CELL STRAIN COS1; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME INHIBITOR INTERACTION; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PROTEINASE INHIBITION; SERUM; STRUCTURE ACTIVITY RELATION; VERO CELL; VIRUS INHIBITION; VIRUS REPLICATION; WEST NILE FLAVIVIRUS;

ANTIVIRAL AGENTS; CATIONS; MODELS, MOLECULAR; PROTEASE INHIBITORS; RNA HELICASES; SERINE ENDOPEPTIDASES; SUBSTRATE SPECIFICITY; VIRAL NONSTRUCTURAL PROTEINS;

EID: 52449113528     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800503y     Document Type: Article

References (43)

1. Merianos, A. Surveillance and response to disease emergence. Curr. Top. Microbiol. Immunol. 2007, 315, 477-509.
2. Centers for Disease Control and Prevention Division of Vector-Borne Infectious Disease; West Nile Virus (http://www.cdc.gov/ncidod/dvbid/westnile/); Dengue (http://www.cdc.gov/ncidod/dvbid/dengue/index.htm); World Health Organisation, Yellow Fever (http://www.who.int/mediacenrre/news/releases/2007/ pr23/en/index.html); Japanese Encephalitis (http://www.path.org/projects/ JE_in_depth.php).
3. Kramer, L. D.; Styer, L. M.; Ebel, G. D. A global perspective on the epidemiology of West Nile virus. Annu. Rev. Entomol. 2008, 53, 61-81.
4. Ferguson, N. M.; Fraser, C.; Donnelly, C. A.; Ghani, A. C.; Anderson, R. M. Public health. Public health risk from the avian H5N1 influenza epidemic. Science 2004, 304, 968-969.
5. Petersen, L. R.; Roehrig, J. T. West Nile virus: a reemerging global pathogen. Emerg. Infect. Dis. 2001, 7, 611-614.
6. Bazan, J. F.; Fletterick, R. J. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology 1989, 171, 637-639.
7. Chambers, T. J.; Weir, R. C.; Grakoui, A.; McCourt, D. W.; Bazan, J. F.; Fletterick, R. J.; Rice, C. M. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 8898-9802.
8. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease inhibitors: current status and future prospects. J. Med. Chem. 2000, 43, 305-341.
9. Abbenante, G.; Fairlie, D. P. Protease inhibitors in the clinic. Med. Chem. 2005, 1, 71-104.
10. Falgout, B.; Pethel, M.; Zhang, Y. M.; Lai, C. J. Both nonstructural proteins NS2b and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J. Virol. 1991, 65, 2467-2475.
11. Nall, T. A.; Chappell, K. J.; Stoermer, M. J.; Fang, N. X.; Tyndall, J. D. A.; Young, P. R.; Fairlie, D. P. Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease. J. Biol. Chem. 2004, 279, 48535-48542.
12. Chappell, K. J.; Nall, T. A.; Stoermer, M. J.; Fang, N. X.; Tyndall, J. D. A.; Fairlie, D. P.; Young, P. R. Site-directed mutagenesis and kinetic studies of the West Nile virus NS3 protease identify key enzyme-substrate interactions. J. Biol. Chem. 2005, 280, 2896-2903.
13. Chappell, K. J.; Stoermer, M. J. R.; Fairlie, D. P.; Young, P. Insights to substrate binding and processing by West Nile virus NS3 protease through combined modeling, protease mutagenesis, and kinetic studies. J. Biol. Chem. 2006, 281, 38448-38458.
14. Erbel, P.; Schiering, N.; D'Arcy, A.; Renatus, M.; Kroemer, M.; Lim, S. P.; Yin, Z.; Keller, T. H.; Vasudevan, S. G.; Hommel, U. Structural basis for the activation of flaviviral NS3 proteases from Dengue and West Nile virus. Nat. Struct. Mol. Biol. 2006, 13, 372-373.
15. Knox, J. E.; Ma, N. L.; Yin, Z.; Patel, S. J.; Wang, W. L.; Chan, W. L.; Ranga Rao, K. R.; Wang, G.; Ngew, X.; Patel, V.; Beer, D.; Lim, S. P.; Vasudevan, S. G.; Keller, T. H. Peptide Inhibitors of West Nile NS3 Protease: SAR Study of Tetrapeptide Aldehyde Inhibitors. J. Med. Chem. 2006, 49, 6585-6590.
16. Shiryaev, S. A.; Kozlov, I. A.; Ratnikov, B. I.; Smith, J. W.; Lebl, M.; Strongin, A. Y. Cleavage preference distinguishes the two-component NS2B-NS3 serine proteinases of Dengue and West Nile viruses. Biochem. J. 2007, 401, 743-752.
17. Shiryaev, S. A.; Ratnikov, B. I.; Aleshin, A. E.; Kozlov, I. A.; Nelson, N. A.; Lebl, M.; Smith, J. W.; Liddington, R. C.; Strongin, A. Y. Switching the substrate specificity of the two-component NS2B-NS3 flavivirus proteinase by structure-based mutagenesis. J Virol. 2007, 81, 4501-4509.
18. Chappell, K. J.; Stoermer, M. J.; Fairlie, D. P.; Young, P. R. Generation and characterization of proteolytically active and highly stable truncated and full-length recombinant West Nile virus NS3. Protein Expression Purif. 2007, 53, 87-96.
19. Aleshin, A. E.; Shiryaev, S. A.; Strongin, A. Y.; Liddington, R. C. Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci. 2007, 16, 795-806.
20. Bera, A. K.; Kuhn, R. J.; Smith, J. L. Functional Characterization of cis and trans Activity of the Flavivirus NS2B-NS3 Protease. J. Biol. Chem. 2007, 282, 12883-12892.
21. Shiryaev, S. A.; Ratnikov, B. I.; Chekanov, A. V.; Sikora, S.; Rozanov, D. V.; Godzik, A.; Wang, J.; Smith, J. W.; Huang, Z.; Lindberg, I.; Samuel, M. A.; Diamond, M. S.; Strongin, A. Y. Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem. J. 2006, 393, 503-511.
22. Ganesh, V. K.; Muller, N.; Judge, K.; Luan, C. H.; Padmanabhan, R.; Murthy, K. H. M. Identification and characterization of nonsubstrate based inhibitors of the essential Dengue and West Nile virus proteases. Bioorg. Med. Chem. 2005, 13, 257-264.
23. Leung, D.; Schroder, K.; White, H.; Fang, N. X.; Stoermer, M. J.; Abbenante, G.; Martin, J. L.; Young, P. R.; Fairlie, D. P. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B cofactor, small peptide substrates, and inhibitors. J. Biol. Chem. 2001, 276, 45762-45771.
24. Li, J.; Lim, S. P.; Beer, D.; Patel, V.; Wen, D.; Tumanut, C.; Tully, D. C.; Williams, J. A.; Jiricek, J.; Priestle, J. P.; Harris, J. L.; Vasudevan, S. G. Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J. Biol. Chem 2006, 280, 28766-28774.
25. Tyndall, J.; Fairlie, D. P. Conformational Homogeneity In Molecular Recognition By Proteolytic Enzymes. J. Mol. Recognit. 1999, 12, 363-370.
26. Fairlie, D. P.; Tyndall, J. D. A.; Reid, R. C.; Wong, A. K.; Abbenante, G.; Scanlon, M. J.; March, D. R.; Bergman, D. A.; Chai, C. L. L.; Burkett, B. A. Conformational Selection Of Inhibitors and Substrates By Proteolytic Enzymes: Implications for Drug Design and Polypeptide Processing. J. Med. Chem. 2000, 43, 1271-1281.
27. Tyndall, J. D. A.; Nall, T.; Fairlie, D. P. Proteases Universally Recognize Beta Strands In Their Active Sites. Chem. Rev. 2005, 105, 973-1000.
28. Rothbard, J. B.; Garlington, S.; Lin, Q.; Kirschberg, T.; Kreider, E.; McGrane, P. L.; Wender, P. A.; Khavari, P. A. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med. 2000, 6, 1253-1257.
29. Mitchell, D. J.; Kim, D. T.; Steinman, L.; Fathman, C. G; Rothbard, J. B. Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res. 2000, 56, 318-325.
30. Samuel, B. U.; Hearn, B.; Mack, D.; Wender, P.; Rothbard, J.; Kirisits, M. J.; Mui, E; Wernimont, S; Roberts, C. W.; Muench, S. P.; Rice, D. W.; Prigge, S. T.; Law, A. B.; McLeod, R. Delivery of antimicrobials into parasites. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 14281-14286.
31. Rothbard, J. B.; Jessop, T. C.; Lewis, R. S.; Murray, B. A.; Wender, P. A. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J. Am. Chem. Soc. 2004, 126, 9506-9507.
32. Thorén, P. E.; Persson, D.; Esbjörner, E. K.; Goksör, M.; Lincoln, P.; Nordén, B. Membrane binding and translocation of cell-penetrating peptides. Biochemistry 2004, 43, 3471-3489.
33. Rothbard, J. B.; Jessop, T. C.; Wender, P. A. Adaptive translocation: the role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. Adv. Drug. Delivery Rev. 2005, 57, 495-504.
34. Zorko, M.; Langel, U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv. Drug. Delivery Rev. 2005, 57, 529-545.
35. Fuchs, S. M.; Raines, R. T. Internalization of cationic peptides: the road less (or more?) traveled. Cell. Mol. Life Sci. 2006, 63, 1819-1822.
36. Fuchs, S. M.; Raines, R. T. Pathway for polyarginine entry into mammalian cells. Biochemistry 2004, 43, 2438-2444.
37. Peterlin-Masic, L.; Kikelj, D. Arginine Mimetics. Tetrahedron 2001, 57, 7073-7105.
38. Abbenante, G.; Leung, D.; Bond, T.; Fairlie, D. P. An efficient Fmoc strategy for the rapid synthesis of peptide pera-nitroanilides. Lett. Pept. Sci. 2000, 7, 347-351.
39. Siev, D. V.; Semple, J. E. Novel hydrazino-carbonyl-amino-methylated polystyrene (HCAM) resin methodology for the synthesis of P1-aldehyde protease inhibitor candidates. Org. Lett. 2000, 2, 19-22.
40. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
41. DeLano, W. L. PyMOL Molecular Graphics System, DeLano Scientific LLC: San Carlos, CA; http://www.pymol.org.
42. Baker, N. A.; Sept, D.; Joseph, S.; Holst, M. J.; McCammon, J. A. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 10037-10041.
43. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.